Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients.
Authors:
- I K TaylorITI K Taylor
- G W TaylorGTG W Taylor
- P RubinPRP Rubin
- J KestersonJKJ Kesterson
- N C BarnesNBN C Barnes
- P J BarnesP J Barnes
Open Access
Abstract
The effect of a single oral dose (800 mg) of zileuton (A-64077), a specific 5-lipoxygenase inhibitor, on the early and late airway responses to inhaled allergen was studied in a randomised, double blind, placebo controlled, and crossover trial in nine subjects with atopic asthma. Leukotriene generation was also assessed in vivo by measuring urinary leukotriene (LT) E4 excretion, and ex vivo by measuring calcium ionophore stimulated whole blood LTB4 production. Zileuton almost completely inhibited ex vivo LTB4 production but reduced urinary excretion of LTE4 by only about half. There was a trend for the early asthmatic response to be less on the day of zileuton treatment, but this did not reach statistical significance (p = 0.08). The zileuton induced reduction in maximum fall in FEV1 in the early asthmatic response was, however, significantly related to the reduction in urinary LTE4 excretion (r = 0.8), but not to the reduction in LTB4 generation ex vivo. There was no significant change in the allergen induced late asthmatic response, or in the increase in airway responsiveness to methacholine following antigen. The results provide some support for the hypothesis that the cysteinyl leukotrienes have a role in the allergen induced early asthmatic response. More complete in vivo inhibition of 5-lipoxygenase may be needed to produce a significant reduction in airway response to allergen challenge.Keywords
This publication has 27 references indexed in Scilit:
- The inhibitory actions of azelastine hydrochloride on the early and late bronchoconstrictor responses to inhaled allergen in atopic asthmaJournal of Allergy and Clinical Immunology, 1989
- Histamine and leukotrienes release in bronchoalveolar fluid during plicatic acid-induced bronchoconstrictionJournal of Allergy and Clinical Immunology, 1989
- Effect of the oral leukotriene D antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D in atopic subjectsJournal of Allergy and Clinical Immunology, 1989
- Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo modelsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1988
- Activity of a Novel Hydroquinone Inhibitor of Leukotriene Synthesis (U-66,858) in the Rhesus Monkey Ascaris ReactorInternational Archives of Allergy and Immunology, 1988
- Effect of inhaled piriprost (U-60, 257) a novel leukotriene inhibitor, on allergen and exercise induced bronchoconstriction in asthma.Thorax, 1986
- Airway Responsiveness to Leukotrienes C4 and D4 and to Methacholine in Patients with Asthma and Normal ControlsNew England Journal of Medicine, 1986
- Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects.Thorax, 1984
- Leukotrienes: Mediators of Immediate Hypersensitivity Reactions and InflammationScience, 1983
- Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytesNature, 1980